AllianceBernstein’s Cardiff Oncology CRDF Stock Holding History

AllianceBernstein’s Portfolio CRDF Stock Details CRDF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$137K	Sell	48,730 -7	-0%	-$14	﹤0.01%	3131
2025 Q4	$137K	Buy	48,737 +7	+0%	+$16	﹤0.01%	3139
2025 Q3	$100K	Hold	48,730	–	–	﹤0.01%	3179
2025 Q2	$154K	Buy	48,730 +38,350	+369%	+$117K	﹤0.01%	3109
2025 Q1	$32.6K	Hold	10,380	–	–	﹤0.01%	3163
2024 Q4	$45K	Hold	10,380	–	–	﹤0.01%	3192
2024 Q3	$27.7K	Hold	10,380	–	–	﹤0.01%	3210
2024 Q2	$23K	Buy	+10,380	New	+$39.1K	﹤0.01%	3221
2017 Q2	–	Sell	-146	Closed	-$12K	–	3150
2017 Q1	$12K	Hold	146	–	–	﹤0.01%	2986
2016 Q4	$22K	Hold	146	–	–	﹤0.01%	3008
2016 Q3	$47K	Sell	146 -44	-23%	-$16K	﹤0.01%	2958
2016 Q2	$62K	Buy	+190	New	+$65.4K	﹤0.01%	2941
2014 Q2	–	Sell	-3	Closed	-$1K	–	3444
2014 Q1	$1K	Hold	3	–	–	﹤0.01%	3521
2013 Q4	$1K	Hold	3	–	–	﹤0.01%	3322
2013 Q3	$1K	Buy	+3	New	+$1.71K	﹤0.01%	3351

Other funds holding CRDF

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Pfizer New York $239M AUM 232.47% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

FLPIM

F.L. Putnam Investment Management Lynnfield, Massachusetts $6.71B AUM 23.99% 1-Year Est. Return

AllianceBernstein's CRDF Position: Q1 2026 in Review

AllianceBernstein reduced its Cardiff Oncology (CRDF) stake by 0.01% in Q1 2026, selling an estimated $14 and leaving 48,730 shares worth $137K. The position accounts for ﹤0.01% of the portfolio, ranked #3131.

AllianceBernstein first reported a position in CRDF in Q3 2013 and has held it in 15 quarters since. The position peaked at $154K in Q2 2025. 116 funds tracked by Wall St. Rank hold CRDF as of Q1 2026.

AllianceBernstein held 48,730 shares of Cardiff Oncology worth $137K as of Q1 2026.
AllianceBernstein sold 7 Cardiff Oncology shares in Q1 2026, an estimated $14.
Cardiff Oncology made up ﹤0.01% of AllianceBernstein's portfolio in Q1 2026, its #3131 holding.
AllianceBernstein first reported a position in Cardiff Oncology in Q3 2013 and has held it in 15 quarters since.
AllianceBernstein's Cardiff Oncology position peaked at $154K in Q2 2025.
116 funds tracked by Wall St. Rank held Cardiff Oncology as of Q1 2026.

Based on AllianceBernstein's 13F filing for Q1 2026, filed 15 May 2026.